BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 17374342)

  • 1. [Orphan drugs in France (2001-2005): access to information and characteristics].
    Baumevieille M; Daveluy A; Aulois-Griot M; Haramburu F
    Therapie; 2007; 62(1):9-16. PubMed ID: 17374342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Orphan drugs: some legal, ethical and economics aspects].
    Pabst JY
    Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.
    Iskrov G; Miteva-Katrandzhieva T; Stefanov R
    Health Policy; 2012 Nov; 108(1):10-8. PubMed ID: 22939047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Market uptake of orphan drugs--a European analysis.
    Picavet E; Annemans L; Cleemput I; Cassiman D; Simoens S
    J Clin Pharm Ther; 2012 Dec; 37(6):664-7. PubMed ID: 22731105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Orphan drugs: availability, reliability and reimbursement].
    Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
    Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Access to orphan drugs in Europe: current and future issues.
    Michel M; Toumi M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Orphan diseases and orphan medicines: a Belgian and European study].
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Orphan drugs].
    Kolár J; Chalabala M; Srámková H
    Ceska Slov Farm; 2001 Mar; 50(2):59-65. PubMed ID: 11288591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Orphan drugs: problem of public health and economic stakes].
    Brandissou S; Yagoubi N; Hasselot N
    Therapie; 1996; 51(6):647-53. PubMed ID: 9164001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [European ordinance on orphan drugs: changes and threats].
    Linthorst GE; Hollak CE
    Ned Tijdschr Geneeskd; 2003 Jan; 147(4):143-5. PubMed ID: 12635543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding orphan drug regulations: an EU and U.S. comparative analysis.
    Grienenberger A
    J Biolaw Bus; 2004; 7(3):58-61. PubMed ID: 15460604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Orphan drugs--medications for patients with rare diseases].
    Thielke D; Thyssen JP; Hansen BJ
    Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EU orphan regulation--ten years of application.
    Michaux G
    Food Drug Law J; 2010; 65(4):639-69, i-ii. PubMed ID: 24479246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Orphanet and the Dutch Steering Committee Orphan Drugs. A European and Dutch databank of information on rare diseases].
    Liem SL
    Ned Tijdschr Tandheelkd; 2008 Nov; 115(11):621-3. PubMed ID: 19058507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Issues surrounding orphan disease and orphan drug policies in Europe.
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hope for patients with rare diseases--"orphan" drugs].
    Kuzelová M; Kubácková K; Palágyi M; Smíd M
    Cas Lek Cesk; 2006; 145(4):296-300. PubMed ID: 16639930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.